Low Readmission and Recurrence Rates of Bacteremia, Endocarditis & Osteomyelitis in Infusion Centers

BOSTON, MA (October 21, 2011) – A multi-center retrospective review of 203 patients treated with long term intravenous antibiotic therapy in physician office infusion centers (POICs) is effective with clinical success rates of 93% in bacteremia, 88% in infective endocarditis, and 93% in osteomyelitis. The 7 participating POICs were able to show low recurrence and readmission rates for bacteremia (13% and 9%, respectively), infective endocarditis (0 and 12%, respectively) and osteomyelitis (5% and 9%, respectively) while maintaining an overall adverse effect rate of 26% (3.5% serious) and catheter infection rate of 0.57 per 1000 catheter days. This suggests that outpatient intravenous antibiotic therapy provided by an Infectious Disease POIC provides a safe and effective treatment option for patients with serious infections requiring long-term therapy.

This study was presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA). For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

The 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) brought together physicians, scientists, and other health care professionals involved in research, patient care, public health, disease prevention, and education in the field of infectious diseases. The meeting showcased the latest news in the field of infectious diseases with emphasis on contemporary trends, including emerging infections, new diagnostic and therapeutic advances. IDSA 2011 took place October 20-23 at the Boston Exhibition and Convention Center in Boston, Massachusetts. For more information, visit www.idsa2011.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.